866-274-4009 Contact Us

Process Development

CONNECT WITH AN EXPERT

The importance of first-time right process development (PD) as a program advances cannot be overstated. It is critical to increasing yields, achieving product quality expectations, and lowering the cost of goods while meeting clinical development and commercial readiness milestones.

The Center for Breakthrough Medicines (CBM) has a PD team with unrivaled experience building and optimizing biopharmaceutical processes for commercial cell and gene therapies.

center for breakthrough medicines cell therapy process development facility

Strategic development drives flawless GMP execution

center for breakthrough medicines biopharmaceutical process development services worker

Developing Strategy

CBM begins with a knowledge transfer of your existing process, or the development of a de novo custom bioprocess from scratch. Our PD team then develops an optimal product strategy to align processes and equipment with future pilot scale and cGMP-scale operations.

Implementing Strategy

Our viral vector and cell therapy process platforms are fully scalable. Processes are designed to meet safety, quality, and yield expectations and are scalable to phase-appropriate production volumes while maintaining critical quality attributes (CQAs) throughout the product lifecycle to commercialization. High throughput capabilities reduce study times by up to 3X.

Technology Transfer

Our PD and cGMP manufacturing teams closely collaborate and are cross-trained to ensure process performance and quality. CBM’s pilot plant enables GMP manufacturing at smaller scale to work out any kinks. From here, we seamlessly transfer your manufacturing process and scale up with pilot and training runs in one location to advance your project to cGMP production.
Learn about CBM’s Analytical Development & Testing >

Viral Vector Process Development

Upstream

  • Suspension and adherent manufacturing platforms for Adeno-Associated Virus (AAV), Adenovirus, Lentivirus, and other novel viral vectors
  • Research cell and virus banking (RCB & RVB)
  • Process development, optimization, and characterization
  • Process validation / BLA-enabling activities
  • Pilot production to support IND-enabling studies

Downstream

  • Viral vector purification capabilities across all processing steps: filtration, chromatography, and ultracentrifugation
  • Process development, optimization, and characterization
  • Process validation / BLA-enabling activities
  • Pilot production to support IND-enabling studies

Drug Product & Analytics

  • High-throughput formulation development
  • Drug product process development and characterization
  • Stability and force-degradation studies
  • Pilot-scale drug product filling to enable tech transfer and support IND-enabling studies
  • In-use stability and device compatibility studies
Learn about CBM’s Viral Vector Capabilities >

Cell Therapy Process Development

Drug Substance

  • Process development and characterization for both autologous and allogeneic products
  • Process validation / BLA-enabling activities
  • Pilot production to support IND-enabling studies
  • Technology transfer / GMP readiness

Drug Product

  • Formulation development
  • Formulation & fill process automation and closure
  • Cryopreservation cycle development
  • Container closure development
  • In-use stability and device compatibility studies
Learn about CBM’s Cell Therapy Capabilities >